BCL2 and neoplasm: We conducted genomic analysis using paired tumor tissue samples at diagnosis and relapse and observed frequent occurrence of mutations in CREBBP and EZH2, which are involved in lymphomagenesis and progression as a chromatin regulator, as well as mutations in BNFRSF14 and BCL2 as previously reported [34].